5 Tiny Cryptos That Could Soar During 2024 Crypto Bull Run One of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.

Get His #1 Coin For 2024 FREE By Clicking Here

Alane Barnes Biography and Net Worth

Insider of BioCryst Pharmaceuticals

Alane P. Barnes serves as Senior Vice President, Chief Legal Officer and Corporate Secretary of the Company. She joined BioCryst in July 2006 as its General Counsel. She was named Corporate Secretary in 2007, was named Vice President, General Counsel & Corporate Secretary in 2011, and was named Senior Vice President, Chief Legal Officer, and Corporate Secretary in 2018. She was named as an executive officer in 2013. Ms. Barnes is responsible for all legal affairs of the company including SEC co pliance, corporate governance, IP strategy and management, licensing transactions, government contract negotiations and management and dispute resolution. She graduated magna cum laude from Cumberland School of Law in 1997 and is a member of Curia Honoris, scholar of merit. Ms. Barnes received her B.S. in Natural Science with a concentration in biology and chemistry from UAB. Prior to joining the Company, Ms. Barnes worked for the UAB Research Foundation where she managed intellectual property, negotiated license transactions and facilitated the emergence of new companies based on university technology. Prior to employment at the UAB Research Foundation Ms. Barnes practiced corporate law with a prominent law firm in Birmingham, Alabama. Ms. Barnes is currently a Board member and the President of the Research Triangle Area Association of Corporate Counsel and regularly speaks at national conferences regarding the pharmaceutical business and at women’s success conferences. She is a 2010 graduate of MOMENTUM, an organization geared toward building leadership in women.

What is Alane P. Barnes' net worth?: The estimated net worth of Alane P. Barnes is at least $548,109.00 as of December 11th, 2020. Ms. Barnes owns 121,802 shares of BioCryst Pharmaceuticals stock worth more than $548,109 as of April 18th. This net worth evaluation does not reflect any other assets that Ms. Barnes may own. Additionally, Ms. Barnes receives an annual salary of $655,330.00 as Insider at BioCryst Pharmaceuticals. Learn More about Alane P. Barnes' net worth.
How old is Alane P. Barnes?: Ms. Barnes is currently 58 years old. There are 8 older executives and no younger executives at BioCryst Pharmaceuticals. The oldest executive at BioCryst Pharmaceuticals is Dr. Yarlagadda S. Babu, Chief Discovery Officer, who is 71 years old. Learn More on Alane P. Barnes' age.
What is Alane P. Barnes' salary?: As the Insider of BioCryst Pharmaceuticals, Inc., Ms. Barnes earns $655,330.00 per year. There are 5 executives that earn more than Ms. Barnes. The highest earning executive at BioCryst Pharmaceuticals is Mr. Jon P. Stonehouse, CEO, President & Executive Director, who commands a salary of $1,150,000.00 per year. Learn More on Alane P. Barnes' salary.
How do I contact Alane P. Barnes?: The corporate mailing address for Ms. Barnes and other BioCryst Pharmaceuticals executives is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. BioCryst Pharmaceuticals can also be reached via phone at (919) 859-1302 and via email at [email protected]. Learn More on Alane P. Barnes' contact information.
Has Alane P. Barnes been buying or selling shares of BioCryst Pharmaceuticals?: Alane P. Barnes has not been actively trading shares of BioCryst Pharmaceuticals within the last three months. Most recently, Alane P. Barnes sold 13,741 shares of the business's stock in a transaction on Friday, December 11th. The shares were sold at an average price of $7.96, for a transaction totalling $109,378.36. Following the completion of the sale, the vice president now directly owns 121,802 shares of the company's stock, valued at $969,543.92. Learn More on Alane P. Barnes' trading history.
Who are BioCryst Pharmaceuticals' active insiders?: BioCryst Pharmaceuticals' insider roster includes George Abercrombie (Director), Yarlagadda Babu (Insider), Alane Barnes (Insider), Anthony Doyle (CFO), Nancy Hutson (Director), Vincent Milano (Director), William Sheridan (Insider), and Jon Stonehouse (CEO). Learn More on BioCryst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of BioCryst Pharmaceuticals?: During the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 4,000 shares worth more than $31,920.00. The most recent insider tranaction occured on June, 15th when Director Machelle Sanders sold 4,000 shares worth more than $31,920.00. Insiders at BioCryst Pharmaceuticals own 4.4% of the company. Learn More about insider trades at BioCryst Pharmaceuticals.
Information on this page was last updated on 6/15/2023.

Alane P. Barnes Insider Trading History at BioCryst Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/11/2020	Sell	13,741	$7.96	$109,378.36	121,802
12/4/2020	Sell	13,741	$6.23	$85,606.43	121,802
11/18/2019	Buy	20,000	$1.45	$29,000.00	102,061
11/30/2018	Sell	44,290	$9.07	$401,710.30
9/14/2016	Sell	8,357	$4.27	$35,684.39	79,377
6/19/2015	Sell	3,000	$15.00	$45,000.00

Alane P. Barnes Buying and Selling Activity at BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Company Overview

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Today's Range

Now: $4.50

$4.49

$4.71

50 Day Range

MA: $5.25

$4.58

$5.95

2 Week Range

Now: $4.50

$4.45

$9.06

Volume

2,956,572 shs

Average Volume

3,284,773 shs

Market Capitalization

$927.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.9

The #1 Crypto for 2024

From InvestorPlace | Ad

Get His #1 Coin For 2024 FREE By Clicking Here

Alane Barnes Biography and Net Worth

What is Alane P. Barnes' net worth?

How old is Alane P. Barnes?

What is Alane P. Barnes' salary?

How do I contact Alane P. Barnes?

Has Alane P. Barnes been buying or selling shares of BioCryst Pharmaceuticals?

Who are BioCryst Pharmaceuticals' active insiders?

Are insiders buying or selling shares of BioCryst Pharmaceuticals?